Methylenedioxybenzylamphetamine

Methylenedioxybenzylamphetamine
Names
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-benzylpropan-2-amine
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
PubChem CID
UNII
InChI
  • InChI=1S/C17H19NO2/c1-13(18-11-14-5-3-2-4-6-14)9-15-7-8-16-17(10-15)20-12-19-16/h2-8,10,13,18H,9,11-12H2,1H3
    Key: DWLUHTUYTBWOLO-UHFFFAOYSA-N
SMILES
  • C1=C3C(=CC=C1CC(C)NCC2=CC=CC=C2)OCO3
Properties
Chemical formula
 C17H19NO2
Molar mass 269.343 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

Methylenedioxybenzylamphetamine, abbreviated MDBZ, and systematically named 3,4-methylenedioxy-N-benzylamphetamine, is a psychedelic drug. It is the N-benzyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. MDBZ produces few to no effects. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ.[1]

Legality

United Kingdom

MDBZ is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ↑ "House of Commons Hansard Written Answers for 23 July 1996 (pt 10)".
  2. ↑ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.